Replies to post #150873 on Biotech Values

[DewDiligence]

Re: BCRX-Presidio merger

The latest info on Presidio’s PPI-668 (an NS5A inhibitor) are the 3-day monotherapy data reported in Jun 2012 (#msg-76993511).

I continue to maintain that BCRX’s nucleoside drug is based on obsolete and discredited technology (#msg-65152679).

All told, therefore, combining these two HCV drugs does not exactly seem like a winning formula for commercial success.

[DewDiligence]

BCRX’s BCX4161 is now on FDA clinical hold:

http://www.sec.gov/Archives/edgar/data/882796/000119312512480941/d444881d8k.htm

The FDA will provide a letter within 30 days outlining the reasons for the clinical hold and the information required to have the hold removed. The Company had previously guided the initiation of Phase 1 testing in the United States before the end of 2012. The Company now estimates that Phase 1 testing of BCX4161 will be delayed approximately three months.

What a debacle the BCRX-Presidio merger has become.

[DewDiligence]

BCRX, Presidio terminate merger:

http://finance.yahoo.com/news/biocryst-pharmaceuticals-presidio-pharmaceuticals-mutually-110000316.html

Not a surprise in light of the recent blowup of BRCX's pipeline.